Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ANIXA BIOSCIENCES INC (ANIX : NSDQ)

• Company Description    Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $2.95 Daily Weekly Monthly 20 Day Moving Average: 59,534 shares Shares Outstanding: 32.92 (millions) Market Capitalization: $97.11 (millions) Beta: 0.58 52 Week High: $4.20 52 Week Low: $2.07 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.67% -2.47% 12 Week -16.90% -24.55% Year To Date 27.16% 13.53%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3150 Almaden Expressway Suite 250 - San Jose,CA 95118 USA ph: 408-708-9808 fax: 631-549-5974 mcatelani@anixa.com http://www.anixa.com

• General Corporate Information    Officers Amit Kumar - Chief Executive Officer and Chairman Michael J. Catelani - President; Chief Operating Officer and Chief Finan Lewis H. Titterton, Jr - Director Arnold Baskies - Director Emily Gottschalk - Director Peer Information ANIXA BIOSCIENCES INC (CORR.) ANIXA BIOSCIENCES INC (RSPI) ANIXA BIOSCIENCES INC (CGXP) ANIXA BIOSCIENCES INC (BGEN) ANIXA BIOSCIENCES INC (GTBP) ANIXA BIOSCIENCES INC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03528H109 SIC: 2834 Fiscal Year Fiscal Year End: October Last Reported Quarter: 07/01/25 Next Expected EPS Date: 01/09/26 Share - Related Items Shares Outstanding: 32.92 Most Recent Split Date: 6.00 (0.04:1) Beta: 0.58 Market Capitalization: $97.11 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.38 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 01/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.17 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 30.00% vs. Previous Quarter: 22.22% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 07/31/25 - -67.45 04/30/25 - -68.17 01/31/25 - -63.31 ROA 07/31/25 - -59.18 04/30/25 - -60.38 01/31/25 - -56.90 Current Ratio 07/31/25 - 8.45 04/30/25 - 8.89 01/31/25 - 9.35 Quick Ratio 07/31/25 - - 04/30/25 - 8.89 01/31/25 - 9.35 Operating Margin 07/31/25 - - 04/30/25 - - 01/31/25 - - Net Margin 07/31/25 - - 04/30/25 - - 01/31/25 - - Pre-Tax Margin 07/31/25 - - 04/30/25 - - 01/31/25 - - Book Value 07/31/25 - 0.47 04/30/25 - 0.46 01/31/25 - 0.52 Inventory Turnover 07/31/25 - - 04/30/25 - - 01/31/25 - - Debt-to-Equity 07/31/25 - 0.00 04/30/25 - 0.00 01/31/25 - 0.00 Debt-to-Capital 07/31/25 - 0.00 04/30/25 - 0.00 01/31/25 - 0.00

Powered by Zacks Investment Research ©